Edition:
United States

Profile: Acceleron Pharma Inc (XLRN.O)

XLRN.O on Consolidated Issue listed on NASDAQ Global Market

35.92USD
15 Dec 2017
Change (% chg)

$-0.08 (-0.22%)
Prev Close
$36.00
Open
$36.10
Day's High
$36.10
Day's Low
$35.39
Volume
1,100,623
Avg. Vol
395,213
52-wk High
$40.35
52-wk Low
$23.07

Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas.

Luspatercept is designed to promote red blood cell production through a mechanism, and it is developing luspatercept with Celgene Corporation (Celgene) to treat anemia and associated complications in myelodysplastic syndromes (MDS), beta-thalassemia, and myelofibrosis. Celgene is conducting a Phase III clinical trial with luspatercept in patients with very low, low and intermediate risk MDS per the Revised International Prognostic Scoring System, the MEDALIST trial. In addition to the Phase III clinical trial, it is conducting two Phase II clinical trials of luspatercept in patients with MDS. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. Sotatercept is being studied through investigator-initiated clinical trials in multiple myeloma, Diamond-Blackfan anemia and myelofibrosis.

The Company is developing dalantercept primarily for use in combination with vascular endothelial growth factor (VEGF) pathway inhibitors to produce outcomes for cancer patients. It is evaluating dalantercept in combination with axitinib, a tyrosine kinase inhibitor of the VEGF pathway, for the treatment of renal cell carcinoma in the DART trial, a two part Phase II clinical trial. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles. The Company has completed a Phase I clinical trial with ACE-083 in healthy volunteers. It has completed the Phase I clinical trial and also initiated a Phase II clinical trial with ACE-083 in patients with facioscapulohumeral dystrophy (FSHD).

Company Address

Acceleron Pharma Inc

128 Sidney St
CAMBRIDGE   MA   02139-4239
P: +1617.6499200
F: +1617.6499988

Company Web Links